GlobeNewswire: Allergy Therapeutics Contains the last 10 of 22 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T08:10:56ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2022/03/03/2396120/0/en/Interim-Results-for-the-six-months-ended-31-December-2021.html?f=22&fvtc=4&fvtv=36030Interim Results for the six months ended 31 December 20212022-03-03T12:00:00Z<![CDATA[Allergy Therapeutics plc(“Allergy Therapeutics” or the “Company” or the “Group”)]]>https://www.globenewswire.com/news-release/2022/01/26/2373343/0/en/Allergy-Therapeutics-announces-FDA-clearance-of-IND-application-for-novel-peanut-allergy-vaccine-candidate-VLP-Peanut.html?f=22&fvtc=4&fvtv=36030Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut2022-01-26T12:00:00Z<![CDATA[Allergy Therapeutics plc(“Allergy Therapeutics”, “ATL” or the “Group”)]]>https://www.globenewswire.com/news-release/2021/10/25/2319712/0/en/Allergy-Therapeutics-announces-positive-top-line-results-from-G309-exploratory-field-trial-to-evaluate-efficacy-and-safety-of-Grass-MATA-MPL.html?f=22&fvtc=4&fvtv=36030Allergy Therapeutics announces positive top line results from G309 exploratory field trial to evaluate efficacy and safety of Grass MATA MPL2021-10-25T11:00:00Z<![CDATA[Allergy Therapeutics plc(“Allergy Therapeutics”, “ATL” or the “Group”)]]>https://www.globenewswire.com/news-release/2021/09/23/2302027/0/en/Preliminary-Results-for-the-Year-ended-30-June-2021.html?f=22&fvtc=4&fvtv=36030Preliminary Results for the Year ended 30 June 20212021-09-23T11:00:00Z<![CDATA[Allergy Therapeutics plc(“Allergy Therapeutics”, “ATL” or the “Group”)]]>https://www.globenewswire.com/news-release/2021/06/24/2252439/0/en/Trading-update.html?f=22&fvtc=4&fvtv=36030Trading update2021-06-24T11:00:00Z<![CDATA[Allergy Therapeutics plc]]>https://www.globenewswire.com/news-release/2020/09/23/2097855/0/en/Allergy-Therapeutics-plc-Preliminary-Results-for-the-year-ended-30-June-2020.html?f=22&fvtc=4&fvtv=36030 Allergy Therapeutics plc Preliminary Results for the year ended 30 June 20202020-09-23T11:00:00Z<![CDATA[Allergy Therapeutics plc]]>https://www.globenewswire.com/news-release/2020/09/03/2088324/0/en/Allergy-Therapeutics-secures-virus-like-particle-VLP-technology-platform-to-broaden-vaccine-pipeline-through-licensing-agreements-with-Saiba-AG-and-DeepVax-GmbH.html?f=22&fvtc=4&fvtv=36030Allergy Therapeutics secures virus-like particle (“VLP”) technology platform to broaden vaccine pipeline through licensing agreements with Saiba AG and DeepVax GmbH2020-09-03T11:00:00Z<![CDATA[Allergy Therapeutics plc (“Allergy Therapeutics”, “ATL” or the “Group”), Saiba AG(“Saiba”) and DeepVax GmbH (“DeepVax”)]]>https://www.globenewswire.com/news-release/2020/03/04/1994976/0/en/Allergy-Therapeutics-Interim-Results-for-the-six-months-ended-31-December-2019.html?f=22&fvtc=4&fvtv=36030Allergy Therapeutics Interim Results for the six months ended 31 December 20192020-03-04T12:00:00Z<![CDATA[Allergy Therapeutics plc(“Allergy Therapeutics”, “ATL” or the “Group”)Interim Results for the six months ended 31 December 2019]]>https://www.globenewswire.com/news-release/2020/01/29/1976690/0/en/Allergy-Therapeutics-publishes-encouraging-new-data-for-peanut-allergy-vaccine-candidate-in-The-Journal-of-Allergy-and-Clinical-Immunology.html?f=22&fvtc=4&fvtv=36030Allergy Therapeutics publishes encouraging new data for peanut allergy vaccine candidate in The Journal of Allergy and Clinical Immunology2020-01-29T12:01:00Z<![CDATA[]]>https://www.globenewswire.com/news-release/2019/06/27/1875464/0/en/Allergy-Therapeutics-plc-Successful-litigation-settlement-relating-to-PQ-Grass-Phase-II-Trial.html?f=22&fvtc=4&fvtv=36030Allergy Therapeutics plc - Successful litigation settlement relating to PQ Grass Phase II Trial2019-06-27T14:47:41Z<![CDATA[Allergy Therapeutics plc(“Allergy Therapeutics”, “ATL” or the “Group”)]]>